Atara Biotherapeutics Inc (NASDAQ:ATRA)

0.6956
Delayed Data
As of Dec 07
 +0.0357 / +5.41%
Today’s Change
0.20
Today|||52-Week Range
5.64
-78.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$66.2M

Company Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Contact Information

Atara Biotherapeutics, Inc.
2380 Conejo Spectrum Street
Thousand Oaks California 91320
P:(805) 623-4211
Investor Relations:
(805) 395-9669

Employees

Shareholders

Other institutional63.13%
Mutual fund holders35.73%
Individual stakeholders13.31%

Top Executives

Pascal TouchonPresident, Chief Executive Officer & Director
Eric HyllengrenChief Financial & Accounting Officer
Manher AJ JoshiChief Medical Officer
Anhco NguyenChief Scientific Officer
K. Amar MuruganChief Legal Officer, Senior VP & General Counsel